Antimicrobial Susceptibility Testing Market by Product Type (Instruments, Reagents & Kits, Services), Test Type (Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, Antiparasitic Susceptibility Testing), Method, Application, End User
Description
The Antimicrobial Susceptibility Testing Market was valued at USD 4.02 billion in 2024 and is projected to grow to USD 4.25 billion in 2025, with a CAGR of 6.02%, reaching USD 6.43 billion by 2032.
A concise and compelling introduction that explains the critical clinical role of antimicrobial susceptibility testing and frames strategic priorities for stakeholders
Antimicrobial susceptibility testing underpins clinical decision making, infection control, and public health surveillance by defining the susceptibility profile of pathogens to antimicrobial agents. As resistance mechanisms diversify and therapeutic options narrow, accurate and timely testing becomes a critical enabler of appropriate therapy, antimicrobial stewardship, and containment measures. Contemporary laboratories must therefore balance the competing imperatives of rapid turnaround, diagnostic accuracy, and operational efficiency while navigating evolving regulatory expectations and payer environments.
Technological advances have expanded the diagnostic toolkit beyond classical phenotypic assays to include molecular diagnostics and hybrid workflows that integrate genotypic signals with phenotypic readouts. This evolution is mirrored by transformations in laboratory workflows, data management, and clinician-facing decision support. Consequently, AST stakeholders-from instrument manufacturers and reagent suppliers to clinical laboratories and public health entities-face pressing choices about investment priorities, interoperability, and partnerships. The following executive summary distills these dynamics into a concise narrative designed to inform strategic planning and operational execution across the AST ecosystem.
Illuminating the transformative technological, operational, and commercial shifts that are redefining how antimicrobial susceptibility testing is delivered and used clinically
The landscape of antimicrobial susceptibility testing is being reshaped by a set of transformative shifts that are altering how tests are designed, performed, interpreted, and commercialized. Automation is reducing manual throughput constraints while improving reproducibility, and molecular techniques are enabling earlier detection of resistance determinants that inform targeted therapies. Taken together, these technologies are narrowing the latency between specimen collection and actionable results, thereby strengthening antimicrobial stewardship efforts and improving patient outcomes.
Concurrently, data analytics and machine learning are bringing new capabilities for interpreting complex results and flagging emerging resistance patterns, which is fostering tighter integration between laboratory information systems and clinical decision support. Moreover, the commercialization model is evolving: vendors increasingly offer instrument-plus-reagent bundles, subscription services, and outcome-based contracts to align incentives with laboratory and payer objectives. Regulatory frameworks and reimbursement pathways are also adapting, creating both hurdles and opportunities for novel assays. As a result, organizations must reassess workflows, talent requirements, and partnership strategies to fully exploit these shifts while mitigating operational and compliance risks.
Assessing how United States tariff changes in 2025 are prompting strategic sourcing shifts, supply chain resilience measures, and procurement adaptations across the AST value chain
The introduction of new tariffs in 2025 has introduced an additional strategic variable affecting procurement, sourcing, and cost structures across the AST supply chain. For organizations that rely on imported instrumentation, consumables, and specialized reagents, increased duties have amplified the total landed cost and encouraged a reevaluation of supplier selection criteria. In response, procurement and supply chain leaders are accelerating diversification efforts, exploring alternative manufacturers, and increasing the use of buffer inventory and safety stocks to protect clinical continuity.
These adjustments are not limited to buying patterns. Manufacturers and distributors are reassessing manufacturing footprints, with some accelerating nearshoring initiatives to reduce exposure to cross-border tariff volatility. Meanwhile, laboratory leaders are revisiting procurement frameworks to include multi-year agreements and strategic partnerships that provide price stability and prioritized access during constrained supply conditions. Importantly, any short-term cost pressure must be weighed against long-term performance and regulatory compliance considerations, since substitution of reagents or platforms can have downstream impacts on assay comparability and clinical interpretation. Therefore, organizations should adopt a balanced approach that combines tactical supply chain measures with strategic collaboration to preserve diagnostic quality while responding to tariff-driven market shifts.
Comprehensive segmentation-driven insights that connect product architectures, test types, methods, applications, and end users to targeted strategic decisions
A granular understanding of segmentation is essential for aligning product development and commercial strategies with end-user needs. From a product perspective, the AST ecosystem comprises instruments, reagents and kits, and services. Instruments include both automated systems and manual instruments, with automated systems further differentiated into automated analyzers and automated plate readers. Reagents and kits span antibiotic susceptibility kits and microbial identification kits, while services encompass analytical testing services and custom testing solutions. This product architecture informs decisions about platform modularity, consumable consumption patterns, and aftermarket support models.
Test-type segmentation highlights distinct clinical and operational use cases: antibacterial susceptibility testing remains the core clinical demand driver, while antifungal, antiparasitic, and antiviral susceptibility testing address specialized therapeutic and public health requirements. Method-based segmentation further clarifies technical strategy: qualitative methods are represented by agar dilution, automated AST, disk diffusion, and genotypic methods, whereas quantitative approaches include broth macrodilution and Etest methods. These methodological distinctions influence regulatory pathways, validation burden, and laboratory workflow design.
Application segmentation separates clinical diagnostics from drug discovery and development and epidemiology; each application imposes unique performance requirements, throughput expectations, and reporting conventions. Finally, end users comprise academic and government research institutes, hospitals and diagnostic centers, and pharmaceutical and biotechnology companies, each with different procurement cycles, decision criteria, and service expectations. By synthesizing these segmentation layers, stakeholders can prioritize investment in platform features, validation studies, and commercial channels that map most directly to the needs of targeted customers.
Key regional dynamics that shape diagnostic adoption, regulatory approaches, and partnership opportunities across Americas, Europe, Middle East & Africa, and Asia-Pacific
Regional dynamics exert a powerful influence over adoption patterns, regulatory approaches, and partnership opportunities within the AST landscape. In the Americas, clinical laboratories and centralized reference centers prioritize rapid turnaround and integration with electronic health records, and they often operate within reimbursement and regulatory frameworks that favor validated, high-throughput platforms. Consequently, commercial strategies that emphasize interoperability, service reliability, and evidence linking diagnostic timeliness to clinical outcomes resonate strongly in this region.
In Europe, Middle East & Africa, regulatory heterogeneity and varying procurement mechanisms shape demand. National public health agencies and regional surveillance programs are important adopters, and collaborative procurement frameworks can influence vendor selection. In addition, some markets in this region place a premium on standards harmonization and cross-border data sharing to support surveillance efforts, which creates opportunities for standardized assays and interoperable reporting solutions.
Asia-Pacific presents a mix of rapid private-sector adoption, expanding local manufacturing capabilities, and pronounced price sensitivity in certain markets. Growing laboratory networks and investments in diagnostic infrastructure support increasing demand for both high-throughput systems and cost-effective rapid assays. Taken together, these regional differences suggest that tailored market entry and commercialization approaches-reflecting local regulatory nuance, pricing dynamics, and distribution models-are essential for sustained adoption and competitive success.
High-impact company-level insights that reveal competitive positioning, partnership models, and commercial approaches shaping the antimicrobial susceptibility testing ecosystem
Competitive dynamics within the AST ecosystem are characterized by a mix of established platform providers, specialized innovators, and emerging service-focused entrants. Incumbent firms typically leverage integrated instrument-reagent systems and global service networks to deliver predictable performance and aftermarket support. Conversely, niche innovators often differentiate through rapid molecular assays, point-of-need solutions, or unique analytical software that enhances interpretive confidence. This competitive polarity creates fertile ground for strategic partnerships, co-development agreements, and targeted acquisitions that combine platform scale with technological novelty.
Service providers and contract laboratories are also reshaping the competitive landscape by offering outsourced testing, validation services, and custom assay development, which appeal to pharmaceutical developers and academic consortia. At the same time, vendors are experimenting with alternative commercial models-such as reagent subscription contracts and performance-based arrangements-that align supplier incentives with laboratory throughput and clinical outcomes. For buyers, the overarching implication is the need to evaluate partners not only on technical attributes but also on long-term service commitments, data stewardship practices, and the ability to co-invest in validation and training initiatives that support sustainable implementation.
Actionable and prioritized recommendations for industry leaders to strengthen resilience, accelerate adoption, and align diagnostic innovation with clinical imperatives
Industry leaders should pursue a coherent strategy that aligns technological investments with clinical needs and operational realities. First, prioritize platform modularity that allows laboratories to adopt automated analyzers or manual instruments as appropriate, while ensuring consumable continuity through validated reagent kits and robust supply agreements. Second, integrate genotypic and phenotypic workflows to enhance diagnostic confidence and reduce time-to-result, complemented by data analytics that translate complex outputs into clinician-ready recommendations.
Operationally, diversify supply chains to reduce exposure to tariff-driven disruptions and forge long-term agreements that include contingency provisions. Invest in workforce training and remote support capabilities to maximize uptime and reduce the risk of implementation failure. From a commercialization perspective, engage early with regulatory agencies and reimbursement stakeholders to clarify evidence requirements and create value propositions that emphasize patient outcomes and cost avoidance. Finally, pursue collaborative research partnerships with academic and public health institutions to validate novel assays in real-world settings and to establish the epidemiologic relevance of new diagnostic endpoints. These combined actions will strengthen resilience, accelerate adoption, and enhance the clinical utility of AST solutions.
Transparent and reproducible research methodology detailing primary stakeholder engagement, secondary analysis, triangulation, and validation processes employed in this assessment
The findings and recommendations presented here are based on a mixed-methods research approach that combines primary stakeholder engagement with rigorous secondary analysis and iterative validation. Primary research included structured interviews with laboratory directors, procurement professionals, clinical microbiologists, and diagnostics developers, complemented by site visits to reference laboratories to observe workflow integration and instrument performance under operational conditions. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, and product technical specifications to ensure technical accuracy and contextual relevance.
Data triangulation was achieved by cross-referencing interview insights with published performance metrics and regulatory filings, followed by synthesis workshops that resolved discrepancies and identified consensus themes. Where appropriate, sensitivity checks were applied to qualitative inferences to surface alternative interpretations and limitation notes. The methodology emphasizes transparency: interview protocols, inclusion criteria for document selection, and validation steps are documented in the supporting appendices. This framework supports reproducibility and enables clients to align the evidence basis with their internal decision-making processes, while acknowledging that evolving technologies and policy changes warrant periodic updates to the analysis.
Concise concluding synthesis that distills strategic imperatives, operational risks, and priorities for stakeholders navigating the evolving antimicrobial susceptibility testing landscape
This executive synthesis underscores a fundamental strategic imperative: the diagnostic community must balance speed, accuracy, and resilience to deliver clinically meaningful antimicrobial susceptibility insights. Technological advances, including automation, molecular assays, and analytics, present clear opportunities to compress time-to-result and enhance interpretive clarity, yet these gains must be matched with robust validation, workforce readiness, and interoperable data systems. Concurrently, external pressures such as tariff-driven supply chain disruptions and heterogeneous regional regulatory environments require proactive procurement and partnership strategies that preserve continuity while enabling innovation.
Looking ahead, stakeholders who successfully integrate modular platforms, diversify sourcing, and engage in collaborative validation efforts will be better positioned to respond to emerging resistance threats and evolving clinical needs. In summary, diagnostic strategy should be guided by a dual focus on operational rigor and adaptive innovation, ensuring that investments deliver measurable improvements in patient care and public health surveillance.
Note: PDF & Excel + Online Access - 1 Year
A concise and compelling introduction that explains the critical clinical role of antimicrobial susceptibility testing and frames strategic priorities for stakeholders
Antimicrobial susceptibility testing underpins clinical decision making, infection control, and public health surveillance by defining the susceptibility profile of pathogens to antimicrobial agents. As resistance mechanisms diversify and therapeutic options narrow, accurate and timely testing becomes a critical enabler of appropriate therapy, antimicrobial stewardship, and containment measures. Contemporary laboratories must therefore balance the competing imperatives of rapid turnaround, diagnostic accuracy, and operational efficiency while navigating evolving regulatory expectations and payer environments.
Technological advances have expanded the diagnostic toolkit beyond classical phenotypic assays to include molecular diagnostics and hybrid workflows that integrate genotypic signals with phenotypic readouts. This evolution is mirrored by transformations in laboratory workflows, data management, and clinician-facing decision support. Consequently, AST stakeholders-from instrument manufacturers and reagent suppliers to clinical laboratories and public health entities-face pressing choices about investment priorities, interoperability, and partnerships. The following executive summary distills these dynamics into a concise narrative designed to inform strategic planning and operational execution across the AST ecosystem.
Illuminating the transformative technological, operational, and commercial shifts that are redefining how antimicrobial susceptibility testing is delivered and used clinically
The landscape of antimicrobial susceptibility testing is being reshaped by a set of transformative shifts that are altering how tests are designed, performed, interpreted, and commercialized. Automation is reducing manual throughput constraints while improving reproducibility, and molecular techniques are enabling earlier detection of resistance determinants that inform targeted therapies. Taken together, these technologies are narrowing the latency between specimen collection and actionable results, thereby strengthening antimicrobial stewardship efforts and improving patient outcomes.
Concurrently, data analytics and machine learning are bringing new capabilities for interpreting complex results and flagging emerging resistance patterns, which is fostering tighter integration between laboratory information systems and clinical decision support. Moreover, the commercialization model is evolving: vendors increasingly offer instrument-plus-reagent bundles, subscription services, and outcome-based contracts to align incentives with laboratory and payer objectives. Regulatory frameworks and reimbursement pathways are also adapting, creating both hurdles and opportunities for novel assays. As a result, organizations must reassess workflows, talent requirements, and partnership strategies to fully exploit these shifts while mitigating operational and compliance risks.
Assessing how United States tariff changes in 2025 are prompting strategic sourcing shifts, supply chain resilience measures, and procurement adaptations across the AST value chain
The introduction of new tariffs in 2025 has introduced an additional strategic variable affecting procurement, sourcing, and cost structures across the AST supply chain. For organizations that rely on imported instrumentation, consumables, and specialized reagents, increased duties have amplified the total landed cost and encouraged a reevaluation of supplier selection criteria. In response, procurement and supply chain leaders are accelerating diversification efforts, exploring alternative manufacturers, and increasing the use of buffer inventory and safety stocks to protect clinical continuity.
These adjustments are not limited to buying patterns. Manufacturers and distributors are reassessing manufacturing footprints, with some accelerating nearshoring initiatives to reduce exposure to cross-border tariff volatility. Meanwhile, laboratory leaders are revisiting procurement frameworks to include multi-year agreements and strategic partnerships that provide price stability and prioritized access during constrained supply conditions. Importantly, any short-term cost pressure must be weighed against long-term performance and regulatory compliance considerations, since substitution of reagents or platforms can have downstream impacts on assay comparability and clinical interpretation. Therefore, organizations should adopt a balanced approach that combines tactical supply chain measures with strategic collaboration to preserve diagnostic quality while responding to tariff-driven market shifts.
Comprehensive segmentation-driven insights that connect product architectures, test types, methods, applications, and end users to targeted strategic decisions
A granular understanding of segmentation is essential for aligning product development and commercial strategies with end-user needs. From a product perspective, the AST ecosystem comprises instruments, reagents and kits, and services. Instruments include both automated systems and manual instruments, with automated systems further differentiated into automated analyzers and automated plate readers. Reagents and kits span antibiotic susceptibility kits and microbial identification kits, while services encompass analytical testing services and custom testing solutions. This product architecture informs decisions about platform modularity, consumable consumption patterns, and aftermarket support models.
Test-type segmentation highlights distinct clinical and operational use cases: antibacterial susceptibility testing remains the core clinical demand driver, while antifungal, antiparasitic, and antiviral susceptibility testing address specialized therapeutic and public health requirements. Method-based segmentation further clarifies technical strategy: qualitative methods are represented by agar dilution, automated AST, disk diffusion, and genotypic methods, whereas quantitative approaches include broth macrodilution and Etest methods. These methodological distinctions influence regulatory pathways, validation burden, and laboratory workflow design.
Application segmentation separates clinical diagnostics from drug discovery and development and epidemiology; each application imposes unique performance requirements, throughput expectations, and reporting conventions. Finally, end users comprise academic and government research institutes, hospitals and diagnostic centers, and pharmaceutical and biotechnology companies, each with different procurement cycles, decision criteria, and service expectations. By synthesizing these segmentation layers, stakeholders can prioritize investment in platform features, validation studies, and commercial channels that map most directly to the needs of targeted customers.
Key regional dynamics that shape diagnostic adoption, regulatory approaches, and partnership opportunities across Americas, Europe, Middle East & Africa, and Asia-Pacific
Regional dynamics exert a powerful influence over adoption patterns, regulatory approaches, and partnership opportunities within the AST landscape. In the Americas, clinical laboratories and centralized reference centers prioritize rapid turnaround and integration with electronic health records, and they often operate within reimbursement and regulatory frameworks that favor validated, high-throughput platforms. Consequently, commercial strategies that emphasize interoperability, service reliability, and evidence linking diagnostic timeliness to clinical outcomes resonate strongly in this region.
In Europe, Middle East & Africa, regulatory heterogeneity and varying procurement mechanisms shape demand. National public health agencies and regional surveillance programs are important adopters, and collaborative procurement frameworks can influence vendor selection. In addition, some markets in this region place a premium on standards harmonization and cross-border data sharing to support surveillance efforts, which creates opportunities for standardized assays and interoperable reporting solutions.
Asia-Pacific presents a mix of rapid private-sector adoption, expanding local manufacturing capabilities, and pronounced price sensitivity in certain markets. Growing laboratory networks and investments in diagnostic infrastructure support increasing demand for both high-throughput systems and cost-effective rapid assays. Taken together, these regional differences suggest that tailored market entry and commercialization approaches-reflecting local regulatory nuance, pricing dynamics, and distribution models-are essential for sustained adoption and competitive success.
High-impact company-level insights that reveal competitive positioning, partnership models, and commercial approaches shaping the antimicrobial susceptibility testing ecosystem
Competitive dynamics within the AST ecosystem are characterized by a mix of established platform providers, specialized innovators, and emerging service-focused entrants. Incumbent firms typically leverage integrated instrument-reagent systems and global service networks to deliver predictable performance and aftermarket support. Conversely, niche innovators often differentiate through rapid molecular assays, point-of-need solutions, or unique analytical software that enhances interpretive confidence. This competitive polarity creates fertile ground for strategic partnerships, co-development agreements, and targeted acquisitions that combine platform scale with technological novelty.
Service providers and contract laboratories are also reshaping the competitive landscape by offering outsourced testing, validation services, and custom assay development, which appeal to pharmaceutical developers and academic consortia. At the same time, vendors are experimenting with alternative commercial models-such as reagent subscription contracts and performance-based arrangements-that align supplier incentives with laboratory throughput and clinical outcomes. For buyers, the overarching implication is the need to evaluate partners not only on technical attributes but also on long-term service commitments, data stewardship practices, and the ability to co-invest in validation and training initiatives that support sustainable implementation.
Actionable and prioritized recommendations for industry leaders to strengthen resilience, accelerate adoption, and align diagnostic innovation with clinical imperatives
Industry leaders should pursue a coherent strategy that aligns technological investments with clinical needs and operational realities. First, prioritize platform modularity that allows laboratories to adopt automated analyzers or manual instruments as appropriate, while ensuring consumable continuity through validated reagent kits and robust supply agreements. Second, integrate genotypic and phenotypic workflows to enhance diagnostic confidence and reduce time-to-result, complemented by data analytics that translate complex outputs into clinician-ready recommendations.
Operationally, diversify supply chains to reduce exposure to tariff-driven disruptions and forge long-term agreements that include contingency provisions. Invest in workforce training and remote support capabilities to maximize uptime and reduce the risk of implementation failure. From a commercialization perspective, engage early with regulatory agencies and reimbursement stakeholders to clarify evidence requirements and create value propositions that emphasize patient outcomes and cost avoidance. Finally, pursue collaborative research partnerships with academic and public health institutions to validate novel assays in real-world settings and to establish the epidemiologic relevance of new diagnostic endpoints. These combined actions will strengthen resilience, accelerate adoption, and enhance the clinical utility of AST solutions.
Transparent and reproducible research methodology detailing primary stakeholder engagement, secondary analysis, triangulation, and validation processes employed in this assessment
The findings and recommendations presented here are based on a mixed-methods research approach that combines primary stakeholder engagement with rigorous secondary analysis and iterative validation. Primary research included structured interviews with laboratory directors, procurement professionals, clinical microbiologists, and diagnostics developers, complemented by site visits to reference laboratories to observe workflow integration and instrument performance under operational conditions. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, and product technical specifications to ensure technical accuracy and contextual relevance.
Data triangulation was achieved by cross-referencing interview insights with published performance metrics and regulatory filings, followed by synthesis workshops that resolved discrepancies and identified consensus themes. Where appropriate, sensitivity checks were applied to qualitative inferences to surface alternative interpretations and limitation notes. The methodology emphasizes transparency: interview protocols, inclusion criteria for document selection, and validation steps are documented in the supporting appendices. This framework supports reproducibility and enables clients to align the evidence basis with their internal decision-making processes, while acknowledging that evolving technologies and policy changes warrant periodic updates to the analysis.
Concise concluding synthesis that distills strategic imperatives, operational risks, and priorities for stakeholders navigating the evolving antimicrobial susceptibility testing landscape
This executive synthesis underscores a fundamental strategic imperative: the diagnostic community must balance speed, accuracy, and resilience to deliver clinically meaningful antimicrobial susceptibility insights. Technological advances, including automation, molecular assays, and analytics, present clear opportunities to compress time-to-result and enhance interpretive clarity, yet these gains must be matched with robust validation, workforce readiness, and interoperable data systems. Concurrently, external pressures such as tariff-driven supply chain disruptions and heterogeneous regional regulatory environments require proactive procurement and partnership strategies that preserve continuity while enabling innovation.
Looking ahead, stakeholders who successfully integrate modular platforms, diversify sourcing, and engage in collaborative validation efforts will be better positioned to respond to emerging resistance threats and evolving clinical needs. In summary, diagnostic strategy should be guided by a dual focus on operational rigor and adaptive innovation, ensuring that investments deliver measurable improvements in patient care and public health surveillance.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of rapid microfluidic AST systems enabling same shift antibiotic optimization
- 5.2. Integration of AI-driven image analysis in AST platforms for enhanced result accuracy
- 5.3. Expansion of next-generation sequencing-based AST assays for comprehensive resistance profiling
- 5.4. Emergence of automated disc diffusion readers reducing manual interpretation variability
- 5.5. Growing demand for multiplexed AST panels targeting multidrug-resistant pathogen detection
- 5.6. Regulatory approval acceleration for microplate-based AST kits to meet urgent clinical needs
- 5.7. Strategic partnerships between diagnostic firms and AI startups to co-develop AST analytics
- 5.8. Implementation of cloud-based AST data management systems for real-time surveillance reporting
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Antimicrobial Susceptibility Testing Market, by Product Type
- 8.1. Instruments
- 8.1.1. Automated Systems
- 8.1.1.1. Automated Analyzers
- 8.1.1.2. Automated Plate Readers
- 8.1.2. Manual Instruments
- 8.2. Reagents & Kits
- 8.2.1. Antibiotic Susceptibility Kits
- 8.2.2. Microbial Identification Kits
- 8.3. Services
- 8.3.1. Analytical Testing Services
- 8.3.2. Custom Testing Solutions
- 9. Antimicrobial Susceptibility Testing Market, by Test Type
- 9.1. Antibacterial Susceptibility Testing
- 9.2. Antifungal Susceptibility Testing
- 9.3. Antiparasitic Susceptibility Testing
- 9.4. Antiviral Susceptibility Testing
- 10. Antimicrobial Susceptibility Testing Market, by Method
- 10.1. Qualitative Methods
- 10.1.1. Agar Dilution
- 10.1.2. Automated Ast
- 10.1.3. Disk Diffusion
- 10.1.4. Genotypic Method
- 10.2. Quantitative Methods
- 10.2.1. Broth Macrodilution
- 10.2.2. Etest Method
- 11. Antimicrobial Susceptibility Testing Market, by Application
- 11.1. Clinical Diagnostics
- 11.2. Drug Discovery & Development
- 11.3. Epidemiology
- 12. Antimicrobial Susceptibility Testing Market, by End User
- 12.1. Academic & Government Research Institutes
- 12.2. Hospitals & Diagnostic Centers
- 12.3. Pharmaceutical & Biotechnology Companies
- 13. Antimicrobial Susceptibility Testing Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Antimicrobial Susceptibility Testing Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Antimicrobial Susceptibility Testing Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Accelerate Diagnostics, Inc.
- 16.3.2. Alifax S.r.l.
- 16.3.3. Becton, Dickinson and Company
- 16.3.4. Bio-Rad Laboratories, Inc.
- 16.3.5. BIOANALYSE Tıbbi Malz. San. ve Tic. Ltd. Sti.
- 16.3.6. Biological Safety Solutions Ltd/Oy
- 16.3.7. BioMérieux SA
- 16.3.8. Bruker Corporation
- 16.3.9. Creative Diagnostics
- 16.3.10. Danaher Corporation
- 16.3.11. Erba Lachema s.r.o.
- 16.3.12. Eurofins Scientific SE
- 16.3.13. F. Hoffmann-La Roche AG
- 16.3.14. Himedia Laboratories Private Limited
- 16.3.15. INTEGRA Biosciences AG
- 16.3.16. Laboratorios Conda, S.A.
- 16.3.17. Launch Diagnostics Limited
- 16.3.18. Leading Biology, Inc.
- 16.3.19. Liofilchem S.r.l.
- 16.3.20. Mast Group Ltd.
- 16.3.21. MP Biomedicals, LLC
- 16.3.22. Pfizer Inc.
- 16.3.23. Qiagen N.V.
- 16.3.24. QuantaMatrix Inc.
- 16.3.25. Resistell AG
- 16.3.26. Synoptics Group
- 16.3.27. Thermo Fisher Scientific Inc.
- 16.3.28. Zhuhai DL Biotech Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
